Objective: How far the results of randomized controlled studies apply to everyday care cannot be judged without regular measurements of outcomes in daily practice. We report on systematic data from a 3-year naturalistic prospective study on panic disorder-agoraphobic (PDA) patients treated with antidepressants in a setting of routine clinical practice. Our aim is to describe the evolution of PDA in relation to the treatments employed, and to explore demographic and clinical characteristics that might be predictive of outcome. Methods: 326 DSM-III-R PDA patients treated with antidepressants in a setting of routine clinical practice were included in a 3-year naturalistic prospective study. We utilized structured and semi-structures instruments, including the Structured Clinical Interview for Diagnosis and the Longitudinal Interview Follow-up Examination. The main antidepressants used were imipramine (39 %), clomipramine (28.5 %) and paroxetine (23.3 %); only 9 % of patients received other antidepressants. Results: 147 patients (45.1 %) stayed on medication throughout the entire period of the follow-up. Of those who interrupted the treatment, 38 % stayed in remission. The probability of achieving at least one remission during the 3-year follow-up period was 96.5 % for PD and 95.9 % for Agoraphobia. Relapses after a period of at least 2 months of complete remission were also common, and the probability of presenting at least one relapse during the 3-years follow-up period was 67.1 % for PD and 39 % for Agoraphobia. The longest period of remission of PD is associated with low severity, medium-lasting course in patients with an onset of the illness in young adulthood. Less severe agoraphobia associated with moderately severe panic attacks appears to confer a better control of phobic behavior. All three major drugs were reasonably well tolerated (only 9 % dropped out because of side effects), with sexual dysfunction and increased appetite being the most common side effects at the last evaluation; in the first phase of the treatment anticholinergic effects and jitteriness were more common with TCAs. Conclusion: Both classical antidepressants and paroxetine emerge as a useful treatment in the long-term management of PDA; paroxetine appears particularly useful in PDA patients because it was significantly less likely to induce jitteriness, thereby reducing barriers to compliance.
References
-
1
Akiskal H S, Mallya G.
Criteria for the “soft” bipolar spectrum: treatment implications.
Psychopharmacol Bull.
1987;
23
68-73
-
2 Akiskal H S, Perugi G, Hantouche F, Haykal R H, Manning S, Connor P. The affective temperament scales of Memphis, Pisa, Paris and San Diego: progress toward a self-rated auto-questionaire version (Temps-A). J Affect Dis (in press)
-
3
. American Psychiatric Association .
Practice guideline for the treatment of patients with panic disorder.
Am J Psychiatry.
1998;
155
((5, Suppl.))
1-34
-
4
Andreassen N C, Endicott J, Spitzer R L, Winokur G.
The family history method using diagnostic criteria. Reliability and validity.
Arch Gen Psychiatry.
1977;
34
((10))
1229-1235
-
5
Bakker A, van Balkom A J, Spinhoven P, Blaauw B M, van Dyck R.
Follow up on the treatment of panic disorder with or without agoraphobia: a quantitative review.
J Nerv Ment Dis.
1998;
186
((7))
414-419
-
6
Ballenger J C, Davidson J R, Lecrubier Y, Nutt D J, Baldwin D S, den Boer J A, Kasper S, Shear M K.
Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety.
J Clin Psychiatry.
1998;
59
((Suppl. 8))
47-54
-
7
Beck A T, Sokol L, Clark D A, Berchick R, Wright F.
A cross-over study of focused cognitive therapy for Panic Disorder.
Am J Psychiatry.
1992;
149
778-783
-
8
Breier A, Charney D S, Heninger G R.
Agoraphobia with panic attacks. Development, diagnostic stability and course of illness.
Arch Gen Psych.
1986;
43
1029-1036
-
9 Breiman L, Friedman J H, Olshen R A, Stone C J. Classification and regression trees. Beltmont, California; Wadsworth 1984
-
10
Burns E L, Thorpe G J, Cavallaro L A.
Agoraphobia 8 years after behavioral treatment: a follow-up study with interview, self-report, and behavioral data.
Behav Ther.
1986;
17
580-591
-
11 Cassano G B, Toni C, Musetti L. Treatment of Panic Disorder. In: Biggio, G, Concas, A, Costa, E (eds) GABAergic Synaptic transmission. New York; Raven Press 1992: 449-460
-
12
Cohen S D, Monteiro W, Marks I M.
Two-year follow-up of agoraphobics after exposure and imipramine.
Br J Psychiatry.
1984;
144
276-281
-
13
Coryel W, Noyes R.
Placebo response in panic disorder.
Am J Psychiatry.
1988;
145
1138-1140
-
14
Cowley D S, Flick S N, Roy-Byrne P P.
Long-term course and outcome in panic disorder: a naturalistic follow-up study.
Anxiety.
1996;
2
13-21
-
15
Curtis G C, Massana J, Udina C, Ayuso J L, Perugi G.
Maintenance of drug therapy of panic disorder.
J Psychiatric Research.
1993;
27
((Suppl. 1))
127-142
-
16
Davidson J R.
The long-term treatment of panic disorder.
J Clin Psychiatry.
1998;
59
((Suppl. 8))
17-21
-
17
Den Boer J A, Slaap B R.
Review of current treatment in panic disorder.
Int Clin Psychopharmacol.
1998;
13
((Suppl. 4))
25-30
-
18
Dunner D, Kumar R.
Paroxetine: a review of clinical experience.
Pharmacopsychiat.
1998;
31
89-101
-
19
Emmelkamp P MG, Kuipers A CM.
Agoraphobia: a follow-up study four years after treatment.
Br J Psychiatry.
1979;
134
352-355
-
20
Faravelli C, Albanesi G.
Agoraphobia with panic attacks. One year prospective follow-up.
Compr Psychiatry.
1987;
28
481-487
-
21
Faravelli C, Paterniti S, Scarpato A.
5-year prospective, naturalistic follow-up study of panic disorder.
Compr Psychiatry.
1995;
36
271-277
-
22
Fava G, Zielezny M, Savron G, Grandi S.
Long-term effects of behavioral treatment for Panic Disorder with Agoraphobia.
Br J Psychiatry.
1995;
166
87-92
-
23
Fyer A J, Liebowitz M R, Gorman J M.
Discontinuation of alprazolam treatment in panic patients.
Am J Psychiatry.
1987;
144
303-308
-
24
Goldberg C.
Cognitive-behavioral therapy for panic: effectiveness and limitations.
Psychiatr Q.
1998;
69
((1))
23-44
-
25 Guy W. Adult personal data inventory. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville; MD, dhew 1976: 93-107
-
26
Hafner R J.
Fresh symptom emergence after intensive behaviour therapy.
Br J Psychiatry.
1976;
129
378-383
-
27
Hoffart A, Hedley L M.
Personality traits among panic disorder with agoraphobia patients before and after symptom-focused treatment.
J Anxiety Disord.
1997;
11
((1))
77-87
-
28
Katschnig H, Amering M, Stolk J M, Klerman G L, Ballenger J C, Briggs A, . et al .
Long-term follow-up after a drug trial for panic disorder.
Br J Psychiatry.
1995;
167
487-494
-
29
Keller M, Lavori P, Friedman B, Nielsen E, Endicott J, McDonald Scott P, . et al .
The longitudinal Interval Follow-up Evaluation. A Comprehensive Method for assessing outcome in perspective longitudinal studies.
Arch Gen Psychiatry.
1987;
44
540-548
-
30
Keller M B, Yonkers K A, Warshaw M G, Pratt C A, Gollan J K, Massion A O, . et al .
Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up.
J Nerv Men Dis.
1994;
182
290-296
-
31 Klein D F. Anxiety reconceptualized. In: Klein DF, Rabkin JG (eds) Anxiety: new research and changing concepts. New York; Raven Press 1980
-
32
Lecrubier Y, Bakker A, Dunbar G, Judge R, . and the collaborative Paroxetine Panic Study Investigators .
A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder.
Acta Psychiatr Scand.
1997;
95
145-152
-
33
Lecrubier Y.
The impact of comorbidity on the treatment of panic disorder.
J Clin Psychiatry.
1998;
59
((Suppl. 8))
11-14
-
34
Lelliott P T, Marks I M, Montero W O, Tsakaris F, Noshirvani H.
Agoraphobics 5 years after imipramine and exposure: outcome and predictors.
J Nerv Men Dis.
1987;
175
599-605
-
35
Lesser I M, Rubin R T, Pecknold S C, Rufkin A, Swinson R P, Lydiard R B, . et al .
Secondary depression in panic disorder and agoraphobia: frequency, severity and response to treatment.
Arch Gen Psychiatry.
1988;
45
437-443
-
36
Liebowitz M R.
Panic disorder as a chronic illness.
J Clin Psychiatry.
1997;
58
((Suppl. 13))
5-8
-
37
Linden M.
Phase IV Research and Drug Utilization Observation Studies.
Pharmacopsychiat.
1997;
30
((1))
1-3
-
38
Linden M.
Therapeutic standards in psychopharmacology and medical decision making.
Pharmacopsychiat.
1994;
27
41-45
-
39
Maier W, Buller R.
One-year follow-up of panic disorder.
Eur Arch Psychiatr Neurol Sci.
1988;
238
105-109
-
40
Marks I.
Phobic disorders four years after treatment: a prospective follow-up.
Br J Psychiatry.
1971;
118
683-688
-
41
Mavissakalian M, Michelson L.
Two-year follow-up of exposure and imipramine treatment of Agoraphobia.
Am J Psychiatry.
1986;
143
1106-1112
-
42
Mavissakalian M, Hamann M S.
DSM-III personality disorder in agoraphobia. II. Changes with treatment.
Compr Psychiatry.
1987;
28
356-361
-
43
Mavissakalian M, Perel J.
Clinical experiments in maintenance and discontinuation of imipramine therapy in Panic Disorder with Agoraphobia.
Arch Gen Psychiatry.
1992;
49
318-323
-
44
Mavissakalian M, Perel J.
Protective effect of imipramine maintenance treatment in panic disorder with agoraphobia.
Am J Psychiatry.
1992;
149
1053-1057
-
45
Milrod B, Busch F.
Long-term outcome of panic disorder: a review of the literature.
J Nerv Ment Dis.
1996;
184
723-730
-
46
Munby M, Johnston D W.
Agoraphobia: the long-term follow-up of behavioural treatment.
Br J Psychiatry.
1980;
137
418-427
-
47
Nagy L M, Krystal J H, Woods S W, Charney D S.
Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder.
Arch Gen Psychiatry.
1989;
46
993-999
-
48
Nagy L M, Krystal J H, Charney D S.
Long-term outcome of Panic Disorder after short-term imipramine and behavioral group treatment.
J Clin Psychopharmacology.
1993;
13
16-24
-
49
Noyes R, Garvey M, Cook B.
Follow-study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants.
J Affective Disorders.
1989;
16
249-257
-
50
Noyes R, Reich J, Christiansen J, Suelzer M, Pfohl B, Coryell W A.
Outcome of Panic Disorder: relationship to dignostic subtypes and comorbidity.
Arch General Psychiatry.
1990;
47
809-818
-
51
Noyes R, Garvey M J, Cook B, Suelzer M.
Controlled discontinuation of benzodiazepine treatment for patients with panic disorder.
Am J Psychiatry.
1991;
148
517-523
-
52
Noyes R, Clancy J, Woodsman C, Holt C S, Suelzer M, Christiansen J, . et al .
Environmental factors related to the outcome of panic disorder: a seven-year follow-up study.
J Nerv Men Dis.
1993;
181
529-533
-
53
O'Rourke D, Fahy T J, Brophy J, Prescott P.
The Galway study of panic disorder III: outcome at 5 to 6 years.
Br J Psychiatry.
1996;
168
462-469
-
54 O'Sullivan G, Marks I M. Long-term outcome of phobic and obessive-compulsive disorders after treatment. In: Noyes R, Burrows GD, Roth M (eds) Handbook of Anxiety. Vol. 4. Amsterdam; Elsevier 1990: 87-108
-
55
Otto W.
Integrated treatment of panic disorder.
J Clin Psychiatry.
1997;
58
36-42
-
56
Pecknold J C.
Discontinuation reactions to alprazolam in panic disorder.
J Psychiatr Res.
1993;
27
((Suppl. 1))
155-170
-
57
Perugi G, Toni C, Benedetti A, Simonetti B, Simoncini M, Torti C, . et al .
Delineating a putative phobic-anxious temperament in 126 panic-agoraphobic patients: toward a rapprochement of European and US views.
J Affect Dis.
1998;
47
((1 - 3))
11-23
-
58
Placidi G F, Signoretta A, Liguori A, Gervasi R, Maremmani I, Akiskal H S.
The semi-structured affective temperament interview (TEMPS-I). Reliability and psychometric properties in 1010 14-26 year old students.
J Affect Dis.
1998;
47
1-10
-
59
Pollack M H.
Long-term management of panic disorder.
J Clin Psychiatry.
1990;
51
11-13
-
60
Pollack M H, Otto M W, Rosenbaum J, Sachs G, O'Neil C, Asher R, . et al .
Longitudinal course of Panic Disorder: finding from the Massachusetts General Hospital Naturalistic Study.
J Clin Psychiatry.
1990;
51
12-16
-
61
Pollack M H, Otto M W.
Long-term course and outcome of panic disorder.
J Clin Psychiatry.
1997;
58
((Suppl. 2))
57-60
-
62
Reich J H.
DSM-III personality disorders and the outcome of treated panic disorder.
Arch Gen Psychiatry.
1988;
145
1149-1152
-
63
Roy-Byrne P P, Cowley D S.
Course and outcome in panic disorder: a review of recent follow-up studies.
Anxiety.
1995;
1
151-160
-
64
Scheibe G, Albus M.
Predictors of outcome in panic disorder: a 5-year prospective follow-up study.
J Affect Disorder.
1996;
41
111-116
-
65
Sheehan D V, Ballenger J, Jacobsen G.
Treatment of endogenous anxiety.
Arch Gen Psychiatry.
1980;
37
51-59
-
66 Sheehan D. The anxiety disease. New York; Bantam Books 1986
-
67
Solyom L, Heseltine G FD, McClure D J, . et al .
Interaction of phenelzine and exposure in phobias.
Can Psychiatr Assn J.
1973;
18
25-32
-
68 Spitzer R L, Williams J BW. Structured clinical interview for DSM-III (SCID). In: Reidel D, Dordrecht (ed) New York, NY; Biometrics Research Department, State Psychiatric Institute 1983
-
69 Spitzer R L, Williams J BW, Gibbon M, First M B. Structured Clinical Interview for DSM-III Personality Disorders (SCID-II). Washington, DC; American Psychiatric Press 1990
-
70
Toni C, Cassano G B, Perugi G, Murri L, Mancino M, Petracca A, . et al .
Psychosensorial and related phenomena in panic disorder and in temporal lobe epilepsy.
Comprehensive Psychiatry.
1996;
37
((2))
125-133
-
71
Tyrer P, Candy J, Kelly D.
A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety.
Psychopharmacology.
1973;
32
237-254
-
72
Tyrer T.
Clinical effects of abrupt withdrawal from tricyclic antidepressants and monoamine oxidase inhibitors after long term treatment.
J Affective Disord.
1984;
6
1-7
-
73
Van Balkom A J, Bakker A, Spinhoven P, Blaauw B M, Smeenk S, Ruesink B.
A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments.
J Nerv Ment Dis.
1997;
185
((8))
510-516
-
74
Van Valkenburg C, Akiskal H S, Puzantian V, . et al .
Anxious depressions: clinical, family history, and naturalistic outcome: comparisons with panic and major depressive disorders.
J Affect Disord.
1984;
6
67-82
-
75
Warshaw M G, Massion A O, Shea M T, Allsworth J, Keller M B.
Predictors of remission in patients with panic with and without agoraphobia: prospective 5-year follow-up data.
J Nerv Ment Dis.
1997;
185
((8))
517-519
-
76 Wittchen H-U. Natural course and spontaneous remissions of untreated anxiety disorders: results of the Munich follow-up study. In: Hand I, Wittchen H-U (eds) Panic and phobias 2. Berlin; Sperlag 1988: 3-17
-
77
Zitrin C M, Klein D F, Woemer M G.
Treatment of agoraphobia with group exposure in vivo and imipramine.
Arch Gen Psychiatry.
1980;
37
63-72
Dr. Giulio Perugi
Institute of Psychiatry
via Roma 67
56100 Pisa
Italy
Telefon: +39-050-992543
eMail: gperugi@psico.med.unipi.it
